Published in Cancer Weekly, May 26th, 1997
Campto is indicated for the treatment of advanced metastatic colorectal cancer that has failed to respond to standard chemotherapy with 5-fluorouracil (5-FU) and folinic acid. Campto was also recently approved in Egypt. The drug has now been approved in 16 countries and is available in 10, including France (through RPR), Japan (through Yakult Honsha Co. Ltd.), and the United States (through Pharmacia & Upjohn).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.